Targeting hypertension with SGLT2 inhibition: the EU-funded SGLT2 HYPE trial

Puntos clave

• The aim is to evaluate the efficacy of SGLT2 inhibition in managing hypertension.
• Randomized trial design evaluating SGLT2 inhibitor treatment compared to control.
• Participants included individuals diagnosed with hypertension.
• Assessment of hypertension biomarkers and blood pressure changes.
• SGLT2 inhibition decreased systolic blood pressure by an average of 5 mmHg (p<0.01).
• Significant improvements in specific hypertension biomarkers were observed post-intervention.
• SGLT2 inhibitors were well tolerated with minimal adverse events reported.